Thrive Wealth Management LLC Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Thrive Wealth Management LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 5.0% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 4,020 shares of the company’s stock after acquiring an additional 192 shares during the period. Thrive Wealth Management LLC’s holdings in AstraZeneca were worth $272,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its position in shares of AstraZeneca by 237.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 123,018 shares of the company’s stock worth $8,331,000 after acquiring an additional 86,610 shares during the period. LPL Financial LLC raised its position in AstraZeneca by 2.4% in the 3rd quarter. LPL Financial LLC now owns 328,458 shares of the company’s stock valued at $22,243,000 after purchasing an additional 7,582 shares in the last quarter. PEAK6 Investments LLC acquired a new position in shares of AstraZeneca during the third quarter worth about $474,000. O Shaughnessy Asset Management LLC increased its stake in shares of AstraZeneca by 5.8% during the third quarter. O Shaughnessy Asset Management LLC now owns 87,410 shares of the company’s stock worth $5,919,000 after buying an additional 4,795 shares during the period. Finally, Mutual Advisors LLC raised its holdings in AstraZeneca by 16.8% in the third quarter. Mutual Advisors LLC now owns 9,923 shares of the company’s stock valued at $672,000 after acquiring an additional 1,430 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 1.1 %

NASDAQ:AZN traded down $0.90 on Thursday, hitting $78.18. 2,796,709 shares of the stock were exchanged, compared to its average volume of 5,608,135. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $80.86. The stock has a market cap of $242.40 billion, a PE ratio of 38.33, a PEG ratio of 1.43 and a beta of 0.48. The stock has a fifty day moving average of $77.14 and a 200-day moving average of $70.20.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. The company had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. As a group, equities analysts expect that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

AZN has been the topic of several research analyst reports. The Goldman Sachs Group began coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday. Finally, Argus lifted their price objective on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Three analysts have rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.